On Wednesday, Prestige Brands Holdings Inc. (NYSE:PBH) saw its price target increase to $95 from the previous $93, while its stock rating was maintained at a Buy. This adjustment comes as DA Davidson includes the company in its Best-of-Breed Bison initiative, which highlights companies that exhibit long-term, superior performance and possess sustainable competitive advantages.
The initiative sets a high bar for inclusion, requiring a company to meet at least 8 out of 12 specific criteria. Prestige Brands surpasses this threshold, satisfying 10 of the criteria. The company stands out within DA Davidson's coverage for having the highest EBITDA margin at 34.5%, in addition to the highest free cash flow margin, which is reported at 22.5%. Furthermore, Prestige Brands maintains a leverage ratio of 2.8x.
DA Davidson notes that Prestige Brands generates predictable and recession-resistant free cash flow. The firm anticipates that the company will produce approximately $1 billion in free cash flow over the next four years. This financial strength is expected to provide Prestige Brands with a variety of meaningful options for capital allocation.
The increase in the price target to $95 is attributed to an updated discounted cash flow (DCF) valuation. DA Davidson sees a 31% upside to the intrinsic value of Prestige Brands, indicating a positive outlook for the company's stock performance.
In other recent news, Prestige Consumer Healthcare Inc. reported first-quarter fiscal 2025 results that exceeded sales and earnings expectations, despite a 4.4% decline in Q1 revenue to $267.1 million and ongoing supply chain and inflationary challenges. The company's adjusted earnings per share (EPS) for the quarter were $0.90, and it generated a robust free cash flow of $54 million.
Additionally, Prestige Consumer Healthcare reduced its debt by $35 million and repurchased $25 million in shares.
In terms of other developments, the company experienced strong international growth, particularly for the Hydralyte brand. Meanwhile, the women's health franchise is stabilizing with a focus on returning Summers Eve to growth.
Looking ahead, Prestige Consumer Healthcare expects full-year revenue to be between $1.125 billion and $1.140 billion, with an adjusted EPS of $4.40 to $4.46 and a free cash flow projection of $240 million or more. Despite declines in the cough-cold and oral care categories, the company maintains a strong performance of TheraTears, Debrox, and Sty in the ear and eye care category.
These are among the recent developments for the company.
InvestingPro Insights
As Prestige Brands Holdings Inc. (NYSE:PBH) garners attention with its inclusion in DA Davidson's Best-of-Breed Bison initiative and an increased price target, real-time data from InvestingPro provides additional context for investors. The company's market capitalization stands at $3.6 billion, and it trades with a P/E ratio of 17.63, reflecting its earnings over the last twelve months as of Q1 2025. Despite a slight decline in revenue growth during this period, with a decrease of 1.49%, the company maintains a robust gross profit margin of 56.09%.
InvestingPro Tips highlight that Prestige Brands exhibits a high shareholder yield and is trading near its 52-week high, with its price reaching 96.41% of this peak. The stock generally trades with low price volatility, which could appeal to investors seeking stability. Additionally, analysts predict the company will be profitable this year, and it has been profitable over the last twelve months. It's noteworthy that while Prestige Brands does not pay a dividend, their liquid assets exceed short-term obligations, which suggests financial flexibility.
For those interested in a deeper analysis, InvestingPro offers more tips on Prestige Brands, which can be found at https://www.investing.com/pro/PBH. These insights could serve as a valuable resource for investors looking to understand the company's performance and potential investment opportunities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.